FASCINATION ABOUT LINSITINIB

The LIDS demo achieved its Main endpoint with statistical significance to the 150mg BID dose. Linsitinib in this demo validated the safety profile observed from the prior oncology studies and importantly demonstrated a favorable safety profile on crucial adverse functions (AEs) of curiosity to the IGF-1R focus on which include Listening to impairme